Rosetta Genomics to Present at Upcoming September Conferences
September 19 2016 - 9:00AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics, today
announces that Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics, will be delivering a corporate
overview at the 2016 Aegis Growth Conference taking place September
20-22, 2016 in Las Vegas and at the Ladenburg Thalmann 2016
Healthcare Conference taking place on September 27, 2016 in New
York City.
2016 Aegis Growth Conference
Date and Time: September
21, 2016, 10:45 AM PDTWebsite: 2016 Aegis Growth
ConferenceFormat: Company PresentationPresenter:
Kenneth A. Berlin
Ladenburg Thalmann 2016 Healthcare Conference
Date and Time: September 27, 2016,
8:30 AM EDTWebsite: Ladenburg Thalmann 2016 Healthcare
ConferenceFormat: Company PresentationPresenter:
Kenneth A. Berlin
Both of Mr. Berlin’s presentations will be webcast live on the
internet and can be accessed by visiting the Investor Relations
section on the Company’s website at www.rosettagx.com. A replay of
the webcasts will be archived on the Rosetta Genomics website for
90 days following the presentation.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company now offers core FISH, IHC and
PCR-based testing capabilities and partnerships in Pathology,
Oncology and Urology that provide additional content and platforms
that complement Rosetta’s microRNA and Next-Gen Sequencing
offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the
diagnosis of indeterminate thyroid FNA smears, as well as the full
RosettaGX™ portfolio of cancer testing services are commercially
available through the Company’s Philadelphia, PA- and Lake Forest,
CA-based CAP-accredited, CLIA-certified labs. For more information
visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects including management presenting
at certain conferences constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta’s
most recently filed Annual Report on Form 20-F, as filed with the
SEC. In addition, any forward-looking statements represent
Rosetta’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160919005804/en/
Rosetta Genomics Contact:Ken Berlin,
267-298-1159President & CEOinvestors@rosettagx.comorRosetta
Genomics Investor Contact:LHAAnne Marie Fields,
212-838-3777afields@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024